Cargando…
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
Thalidomide-based Immunomodulatory Drugs (IMiDs(®)), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal anti...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338861/ https://www.ncbi.nlm.nih.gov/pubmed/28264055 http://dx.doi.org/10.1371/journal.pone.0173507 |